泰格捷通是泰格醫(yī)藥(股票代碼:300347.SZ/3347.HK)全資子公司，成立?于2000年，是中國(guó)領(lǐng)先的醫(yī)療器械(含體外診斷產(chǎn)品)法規(guī)事務(wù)及臨床研?究CRO服務(wù)提供商，覆蓋醫(yī)療器械各領(lǐng)域全生命周期。在過(guò)去的20年中，?我們與來(lái)自30多個(gè)國(guó)家的1700多家醫(yī)療器械研發(fā)及生產(chǎn)企業(yè)建立了長(zhǎng)?期的合作關(guān)系。以我們專業(yè)的服務(wù)能力為客戶降低注冊(cè)風(fēng)險(xiǎn)、縮短項(xiàng)目?周期、節(jié)約研發(fā)經(jīng)費(fèi)，推進(jìn)產(chǎn)品市場(chǎng)化進(jìn)程。?
Tigermed-Jyton?,?a?wholly-owned?subsidiary?of?Tigermed?Group?(?Stock?code?:?300347.SZ/3347.HK?)?,?was?established?in?2000?,?and?is?a?leading?CRO?service?provider?in?China?for?regulatory?affairs?and?clinical?research?ofmedical?debices?(including?in?vitro?diagnostic?products)?,?with?service?covering?the?whole?life?cycle?of?all?fields?of?medical?devices.?In?the?past?20years,we?have?established?long-trem?cooperative?relations?with?more?than1,700?medical?device?R&D?and?manufacture?enterprises?from?more?than?30countries.?With?our?professional?service?capability,?we?can?reduce?registration?risk,?shorten?project?timeline,?save?R&D?funds?and?accelerate?the?process?of?product?marketization.